Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Diabetes Sci Technol ; 11(6): 1112-1123, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28728434

ABSTRACT

BACKGROUND: Blood glucose (BG) regulation is a long-term task for people with diabetes. In recent years, more and more researchers have attempted to achieve automated regulation of BG using automatic control algorithms, called the artificial pancreas (AP) system. In clinical practice, it is equally important to guarantee the treatment effect and reduce the treatment costs. The main motivation of this study is to reduce the cure burden. METHODS: The dynamic R-parameter economic model predictive control (R-EMPC) is chosen to regulate the delivery rates of exogenous hormones (insulin and glucagon). It uses particle swarm optimization (PSO) to optimize the economic cost function and the switching logic between insulin delivery and glucagon delivery is designed based on switching control theory. RESULTS: The proposed method is first tested on the standard subject; the result is compared with the switching PID and the switching MPC. The effect of the dynamic R-parameter on improving the control performance is illustrated by comparing the results of the EMPC and the R-EMPC. Finally, the robustness tests on meal change (size and timing), hormone sensitivity (insulin and glucagon), and subject variability are performed. All results show that the proposed method can improve the control performance and reduce the economic costs. CONCLUSIONS: The simulation results verify the effectiveness of the proposed algorithm on improving the tracking performance, enhancing robustness, and reducing economic costs. The method proposed in this study owns great worth in practical application.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/economics , Drug Costs , Glucagon/administration & dosage , Glucagon/economics , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/economics , Insulin Infusion Systems/economics , Insulin/administration & dosage , Insulin/economics , Pancreas, Artificial/economics , Algorithms , Biomarkers/blood , Blood Glucose/metabolism , Blood Glucose Self-Monitoring/economics , Computer Simulation , Cost Savings , Cost-Benefit Analysis , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/diagnosis , Glucagon/adverse effects , Humans , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Insulin Infusion Systems/adverse effects , Models, Biological , Models, Economic , Pancreas, Artificial/adverse effects , Postprandial Period , Predictive Value of Tests , Signal Processing, Computer-Assisted , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...